Cantor Fitzgerald analyst Pablo Zuanic maintained a Buy rating on Cresco Labs (OTC:CRLBF) Inc on Thursday, setting a price target of $18, which is approximately 98.24% above the present share price of $9.08.
Zuanic expects Cresco Labs Inc to post earnings per share (EPS) of -$0.09 for the fourth quarter of 2020.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Cresco Labs, with an average price target of $11.6.
The analysts price targets range from a high of $18 to a low of $8.4.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $94.26 million and a net profit of $17.73 million. The company's market cap is $1.89 billion.
According to TipRanks.com, Cantor Fitzgerald analyst Pablo Zuanic is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.7% and a 48.04% success rate.
Cresco Labs Inc is a Canada based company engaged in the production and sale of cannabis. The company distribute its products to dispensaries nationwide, including several dispensaries owned and operated by its team. Its product includes Reserve, Remedi, Mindy's. All the revenues of the company were generated in the United States. It has ownership interests in Illinois, Pennsylvania, Ohio, California, Maryland, and Arizona.